Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX

• Imugene dose escalates to the final highest dose (100µg) cohort in Phase I clinical trial of • PD1-Vaxx deemed safe with no dose-limiting toxicities (DLTs) and no serious adverse reactions observed at mid-dose (50µg) level. • The ongoing Phase 1 data represent a clinical proof-of-concept signal for PD1-Vaxx monotherapy with early efficacy signals, and indicate that B-cell activating immunotherap